文档介绍：·90· 中国肺癌杂志2019年2月第22卷第2期 Chin J Lung Cancer, February 2019, , China
Corresponding author: Qinghua ZHOU, E-mail: ******@
Shihui MIN and Qiangqiang ZHENG contributed equally to this study.
【Abstract】 Background and objective The aim of this study is to systematically evaluate the efficacy and ad-
verse effects of Lobaplatin and Cisplatin in the treatment of malignant pleural effusion. Methods The databases of Medline
(PubMed), Embase, Web of Science, Cochrane, Wanfang, CNKI and VIP were retrieved so as to search the studies about the
randomized controlled clinical trials (RCT) that compared the Lobaplatin and Cisplatin for malignant pleural effusion. The
main outcome indicators include objective response rate, complete response, partial response, nephrotoxicity, chest pain, gas-
trointestinal reaction, myelosuppression, fever response and hepatotoxicity. Relative risk was used as the effect size, which was
expressed as 95% confidence interval. The meta-analysis was performed using Stata statistical software. Results A total of
12 RCTs and 720 MPE patients were included. The results showed that the ORR (RR=, 95%CI: -, P<), CR
(RR